Market Cap 29.81M
Revenue (ttm) 14.97M
Net Income (ttm) -61.07M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -407.95%
Debt to Equity Ratio 0.00
Volume 27,100
Avg Vol 58,838
Day's Range N/A - N/A
Shares Out 40.83M
Stochastic %K 100%
Beta -0.66
Analysts Strong Sell
Price Target $6.00

Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapeutic drug candidates for treating auto-immune and inflammatory diseases. Its lead candidate is VTP-1000, which is in Phase 1 clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease. The company is also developing VTP-300, an immunotherapeutic targeting chronic hepatitis B virus infection; VTP-200, a potential non-invasive treatment for persistent hig...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 1865 818 808
Address:
Zeus Building, Unit 6-10 Rutherford Avenue Harwell, Didcot, United Kingdom
SuperGreenToday
SuperGreenToday Dec. 31 at 5:41 PM
0 · Reply
DeltaDomain
DeltaDomain Dec. 25 at 4:12 PM
$BRNS Macro forces may influence direction, yet internal execution remains the decisive factor. Reliability of results matters more than short bursts of momentum. Visible traction across segments would strengthen the thesis. Over time, credibility will hinge on repeatable performance.
0 · Reply
Zaga64
Zaga64 Dec. 19 at 6:40 PM
$BRNS I'm trying to buy but I'm getting this message. Your order is not eligible for electronic entry. Please call a Charles Schwab representative at (800) 435-4000 for assistance with this trade. (AC4205)
0 · Reply
prismmarketview
prismmarketview Dec. 10 at 8:11 PM
Barinthus $BRNS reports positive Phase 1 results for VTP-1000 in celiac disease prismmarketview.com/barinth......
0 · Reply
DARKP00L
DARKP00L Dec. 10 at 1:33 PM
$BRNS 08:02 on Dec. 10 2025 Barinthus Bio Issues Update On First-In-Human Phase 1 Trial Of VTP-1000 In Adults With Celiac Disease #tradeideas
0 · Reply
frontiere
frontiere Dec. 9 at 7:47 PM
$BRNS Barinthus to-be-merged w Clywedog Therapeutics $CLYD — ref=$0.699 Ling now small size — thanks @Alorenz94 for these summaries, look forward to Ph1 VTP-1000 SAD data imminently per Co guidance👍. 🚩Likely disappoint / negative! BUT - 👍already trades at HALF of run-rate cash (~$1.30 cash per sh run rate, 75.67m/40m=$1.89 cash per sh as of 2025-09-30, NEG EV), 👍near historical floor of $0.64, w CLYD merger in 1H26 w backing of prominent bio funds👍. Think here is attractive risk:return setup for either a short term swing or if too negative then a longer term swing. My prior https://stocktwits.com/frontiere/message/621170226
1 · Reply
topstockalerts
topstockalerts Dec. 8 at 12:21 PM
Pre Market Top Gainers PT2 $MTVA $FULC $PAVS $CFLT $BRNS
0 · Reply
Love_To_Learn
Love_To_Learn Dec. 4 at 1:25 PM
$BRNS good addressed the 0.73 issue overlap u causing some issues for markets and beloved its done thanks make it up to u maybe later
0 · Reply
Love_To_Learn
Love_To_Learn Dec. 4 at 12:44 PM
$BRNS rearranging this 0.73 now
0 · Reply
Love_To_Learn
Love_To_Learn Dec. 4 at 12:43 PM
$BRNS noticed some restriction from your end on beloved will have to fix this 0.73* rewire it altogether
0 · Reply
Latest News on BRNS
Vaccitech Promotes Gemma Brown as Chief Financial Officer

Sep 20, 2022, 4:30 PM EDT - 3 years ago

Vaccitech Promotes Gemma Brown as Chief Financial Officer


Vaccitech to Present at the Jefferies Healthcare Conference

Jun 6, 2022, 4:15 PM EDT - 3 years ago

Vaccitech to Present at the Jefferies Healthcare Conference


Vaccitech: Aiming For A Cure In Chronic Hepatitis B

Apr 3, 2022, 7:57 PM EDT - 4 years ago

Vaccitech: Aiming For A Cure In Chronic Hepatitis B


SuperGreenToday
SuperGreenToday Dec. 31 at 5:41 PM
0 · Reply
DeltaDomain
DeltaDomain Dec. 25 at 4:12 PM
$BRNS Macro forces may influence direction, yet internal execution remains the decisive factor. Reliability of results matters more than short bursts of momentum. Visible traction across segments would strengthen the thesis. Over time, credibility will hinge on repeatable performance.
0 · Reply
Zaga64
Zaga64 Dec. 19 at 6:40 PM
$BRNS I'm trying to buy but I'm getting this message. Your order is not eligible for electronic entry. Please call a Charles Schwab representative at (800) 435-4000 for assistance with this trade. (AC4205)
0 · Reply
prismmarketview
prismmarketview Dec. 10 at 8:11 PM
Barinthus $BRNS reports positive Phase 1 results for VTP-1000 in celiac disease prismmarketview.com/barinth......
0 · Reply
DARKP00L
DARKP00L Dec. 10 at 1:33 PM
$BRNS 08:02 on Dec. 10 2025 Barinthus Bio Issues Update On First-In-Human Phase 1 Trial Of VTP-1000 In Adults With Celiac Disease #tradeideas
0 · Reply
frontiere
frontiere Dec. 9 at 7:47 PM
$BRNS Barinthus to-be-merged w Clywedog Therapeutics $CLYD — ref=$0.699 Ling now small size — thanks @Alorenz94 for these summaries, look forward to Ph1 VTP-1000 SAD data imminently per Co guidance👍. 🚩Likely disappoint / negative! BUT - 👍already trades at HALF of run-rate cash (~$1.30 cash per sh run rate, 75.67m/40m=$1.89 cash per sh as of 2025-09-30, NEG EV), 👍near historical floor of $0.64, w CLYD merger in 1H26 w backing of prominent bio funds👍. Think here is attractive risk:return setup for either a short term swing or if too negative then a longer term swing. My prior https://stocktwits.com/frontiere/message/621170226
1 · Reply
topstockalerts
topstockalerts Dec. 8 at 12:21 PM
Pre Market Top Gainers PT2 $MTVA $FULC $PAVS $CFLT $BRNS
0 · Reply
Love_To_Learn
Love_To_Learn Dec. 4 at 1:25 PM
$BRNS good addressed the 0.73 issue overlap u causing some issues for markets and beloved its done thanks make it up to u maybe later
0 · Reply
Love_To_Learn
Love_To_Learn Dec. 4 at 12:44 PM
$BRNS rearranging this 0.73 now
0 · Reply
Love_To_Learn
Love_To_Learn Dec. 4 at 12:43 PM
$BRNS noticed some restriction from your end on beloved will have to fix this 0.73* rewire it altogether
0 · Reply
elmono
elmono Nov. 18 at 10:49 PM
$BRNS going sub 40 cts soon…..
0 · Reply
Alorenz94
Alorenz94 Nov. 18 at 7:41 AM
$BRNS 4 possible scenarios for the VTP-1000 readout. Asked chat to do a probability weighted expected price on: A) strong positive data B) positive but not mind blowing data C) mixed data/inconclusive D) bad/negative Used the price range midpoint for each scenario. Outcome is as follow - $1.91/ share. This excludes merger price action, CLY’s pipeline, and the mentioned stock buyback so upside is likely way higher than $1.91/share.
2 · Reply
Alorenz94
Alorenz94 Nov. 18 at 2:33 AM
$BRNS …..As of the recent Q325 earnings PR, PH 1 SAD is “ongoing with no treatment related serious adverse events reported” (positive indicator for the drug’s safety profile). And 4 clinical data milestones expected within 18mo of the closing of the transaction in 1H 2026. Need closing to be early Q1 lol. Bleeding ATM. H.C. wainwright analyst Yi Chen reiterated his BUY rating on BRNS today and set a PT Of $4/ share today as well for what it’s worth
0 · Reply
Alorenz94
Alorenz94 Nov. 18 at 2:17 AM
$BRNS cash runway of combined company extends through 2027. Transaction expected to close 1H26. Ph 1 SAD data expected Q425: —single ascending dose data readout for VTP-1000 expected before year end. PH 1 MAD data expected 2H26 —enrollment advancing in multiple ascending dose part of AVALON trial, data expected 2H26 Other milestones expected in H1/H2 2026. VTP-850,200,600,500 unclear what will be of these post merger. Looks like the focus is BRNS’ VTP-1000 and Clyewedog’s-101 and 201 inhibitors for Type 1/2 Diabetes.
1 · Reply
Alorenz94
Alorenz94 Nov. 17 at 9:15 PM
$BRNS large Block end of day
0 · Reply
DARKP00L
DARKP00L Nov. 17 at 12:39 PM
$BRNS 07:29 on Nov. 17 2025 HC Wainwright & Co. Maintains Buy on Barinthus Biotherapeutics, Raises Price Target to $4 #tradeideas
0 · Reply
JarvisFlow
JarvisFlow Nov. 17 at 12:29 PM
HC Wainwright & Co. updates rating for Barinthus Biotherapeutics ( $BRNS ) to Buy, target set at 3 → 4.
0 · Reply
skyrockets_Inc
skyrockets_Inc Nov. 11 at 6:37 PM
$BRNS why such a harsh drop?
1 · Reply
elmono
elmono Nov. 10 at 5:04 PM
$BRNS and another nano crap outfit announcing a data delay….starting to become a habit with all these bio zombies 😂😂😂😂
0 · Reply
CometaMan
CometaMan Nov. 10 at 4:51 PM
$BRNS wow! What a drop. Good potential now?
0 · Reply
Alorenz94
Alorenz94 Nov. 10 at 4:43 PM
$BRNS down 30%???
0 · Reply